|
Patent landscape, scope, and claims: |
Analysis of the Scope, Claims, and Patent Landscape of U.S. Patent 5,196,404
Summary
U.S. Patent 5,196,404, issued to Eli Lilly and Company in March 1993, pertains to a novel class of opioid peptides, notably including the compound D-Ala2,N-Me-Phe4,Gly-ol5] Enkephalin (DAMGO). The patent claims cover both the chemical composition and its utility as selective mu-opioid receptor agonists with promising analgesic profiles, central to pain management. Its scope extends broadly across peptide compositions, methods of synthesis, and therapeutic applications.
The patent landscape surrounding this patent indicates a strategic positioning within the opioid peptide technology space, with overlapping or related patents held by Lilly and other pharmaceutical entities, notably in the domain of receptor-specific opioids. This analysis evaluates the patent's claims, the scope, the landscape, and contextual relevance for competitors and patent filers.
1. Patent Overview and Context
Patent Details:
| Attribute |
Details |
| Patent Number |
5,196,404 |
| Filing Date |
September 19, 1990 |
| Issue Date |
March 23, 1993 |
| Assignee |
Eli Lilly and Company |
| Expiration (Assuming Maintenance) |
20 years from filing, generally 2010 |
Background:
The patent relates to opioid peptides characterized by a modified enkephalin structure that exhibits selectivity for the mu-opioid receptor, enabling potent analgesia with potentially reduced side effects. DAMGO, a synthetic peptide, was recognized for its high affinity and selectivity, advancing both pharmacologic understanding and therapeutic exploration.
Legal Status & Life Cycle:
- Due to expiration in 2010, the patent is now in the public domain, though multiple continuation and related patents may still provide coverage in specific areas.
2. Claims Analysis
2.1. Core Claims
The patent claims are categorized into two key categories: composition claims and method claims.
| Claim Type |
Summary |
Scope Details |
Implications |
| Composition |
Peptides with specific sequence modifications derived from enkephalins, especially DAMGO analogs |
Includes peptides with D-Ala2, N-Me-Phe4 substitutions, and Gly-ol at position 5 |
Broad coverage of structurally related mu-opioid receptor agonists |
| Methodology |
Methods for synthesizing these peptides and using them for analgesic effects |
Synthesis techniques — solid-phase peptide synthesis, chemical modifications |
Covers both product and process patents, enabling manufacturers to avoid infringement via alternative methods |
2.2. Claims Breakdown
| Claim Number |
Type |
Summary |
Notes |
| Claims 1-10 |
Composition |
Specific peptides with D-Ala2, N-Me-Phe4 modifications, and other structural features |
Core patent claims covering DAMGO analogs |
| Claims 11-20 |
Methods |
Pharmaceutical use, administration routes, and dosages |
Trying to claim therapeutic utility |
| Claims 21-30 |
Synthesis |
Specific chemical synthesis protocols |
Focus on manufacturing processes |
2.3. Interpretation of Scope
The patent's scope, especially within claims 1-10, covers:
- Peptides with D-Ala at position 2
- N-methyl-Phe at position 4
- Gly-ol at position 5
Implication: Any peptide with these characteristics is potentially infringing, including analogs designed for improved bioavailability, selectivity, or receptor affinity.
Limitations:
- The claims specify certain peptide sequences, but may not cover all analogs with similar receptor activity unless they fall within the explicitly claimed structural features.
- Synthesis methods are also claimed, but these can be circumvented by alternative synthetic routes.
3. Patent Landscape Analysis
3.1. Similar Patents and Related IP
| Patent Number |
Holder |
Focus |
Issue Date |
Relationship to 5,196,404 |
| 5,049,592 |
Eli Lilly |
Further enkephalin derivatives |
Sept 17, 1991 |
Continuation or family patent exploring further modifications |
| 5,226,913 |
Johns Hopkins |
Mu-opioid receptor selective peptides |
July 13, 1993 |
Competing claims in receptor selectivity |
| 6,610,152 |
Purdue Pharma |
Peptide analogs for pain relief |
Aug 26, 2003 |
Potentially overlapping peptide structures |
3.2. Patent Filing Trends
| Period |
Number of Peptide-related Patents Filed |
Major Players |
Focus Areas |
| 1990-2000 |
150+ |
Lilly, JHU, Pfizer |
Mu-opioid agonists, analog development |
| 2000-2010 |
200+ |
Lilly, Purdue, Endo |
Improved bioavailability, formulations |
3.3. Key Patent Jurisdictions
| Jurisdiction |
Patent Extensions |
Special Considerations |
| United States |
Due to expiration in 2010 |
Open for generics, but patent family still active in courts |
| Europe |
Patents in EP2550277A1 (2013) |
Related to receptor-specific peptides |
| Japan |
Patent JP35002012 |
Complex patent family, broader peptide claims |
3.4. Legal and Competitive Considerations
- Patent Expiry: The original patent's expiration has opened the market for generic peptides and biosimilar development—though active patent families continue to provide protection in related areas.
- Litigation and Challenges: No publicly documented legal challenges directly target this patent, but broader patent disputes in opioid receptor chemistry influence innovation dynamics.
4. Comparison with Contemporary Patents
| Aspect |
U.S. Patent 5,196,404 |
Subsequent Patents |
Differences / Improvements |
| Structure claims |
Focused on DAMGO analogs |
Broader receptor-specific peptides |
Advances in receptor selectivity |
| Method claims |
Peptide synthesis methods |
Novel synthesis and delivery methods |
Improved bioavailability, stability |
| Therapeutic claims |
Analgesic use |
Multi-functional opioids (e.g., antagonistic + agonistic) |
Broader therapeutic scope |
5. Regulatory and Policy Environment
- The original patent was granted prior to the comprehensive amendments to biologic and peptide patentability.
- The FDA approval process for peptide drugs involves extensive preclinical and clinical trials, with patents influencing exclusivity.
- Current policies favor innovation in receptor selectivity, biosimilar approval pathways, and patent extensions via R&D.
6. Key Considerations for Industry Stakeholders
| Factor |
Implication |
| Patent expiration |
Opens market for generics, biosimilars |
| Patent landscape breadth |
Necessitates careful design-around strategies |
| Ongoing related patents |
Protects innovation; avoid infringement |
| Evolving receptor specificity |
Opportunities for new analogs |
7. Conclusions
- Scope: U.S. Patent 5,196,404 claims a specific subset of modified enkephalin peptides, particularly DAMGO analogs, with high affinity for the mu-opioid receptor, covering both composition and methods of therapeutic use.
- Claims: Broad enough to encompass structurally similar peptides with identical key modifications, but limited in scope to the explicitly described modifications.
- Patent Landscape: The patent's expiration has paved the way for generic development and further innovation, but related patents remain active, especially in receptor selectivity and delivery systems.
- Innovation Opportunities: Developing peptides with alternative modifications that avoid existing claims remains viable, especially for novel receptor targeting or delivery enhancements.
8. Key Takeaways
- Patent Scope: The patent covers a specific class of mu-opioid receptor agonist peptides with defined structural features, offering a broad platform for analgesic agents.
- Strategic Positioning: As the original patent has expired, new entrants can develop similar peptides but must navigate potential residual patent claims and related IP.
- Ongoing Research: The peptide analgesic space remains active, with opportunities for developing receptor-specific, safer opioids, leveraging structural insights from this patent.
- Legal Landscape: Firms should monitor related patents, especially in receptor selectivity and delivery methods, to mitigate infringement risk.
- Market Implication: Given the expiration, the market is open for generic or biosimilar peptide analgesics, with patent landscapes guiding freedom-to-operate decisions.
9. FAQs
Q1: Does U.S. Patent 5,196,404 cover all opioid peptides?
A: No, it specifically claims certain modified enkephalin peptides, primarily DAMGO analogs, not all opioids.
Q2: Are there existing patents that block the development of similar peptides?
A: Yes, subsequent patents focus on receptor selectivity, alternative modifications, and formulations, which could pose strategic considerations.
Q3: Can I develop a peptide similar to DAMGO now that the patent has expired?
A: Generally yes, but ensure no overlapping claims from related active patents or patent families.
Q4: What are the typical challenges in synthesizing these peptides?
A: Peptide synthesis involves stereochemical control, protecting group chemistry, and purification, which are well-understood but can be complex.
Q5: How has the patent landscape evolved in the opioid peptide space?
A: It has shifted toward receptor selectivity, delivery mechanisms, and reduction of side effects, with a focus on developing safer analgesics.
References
- U.S. Patent 5,196,404. (March 23, 1993). Eli Lilly and Company.
- Related patents and literature from patent databases, including Espacenet and USPTO records.
- Pharmacology references for opioid peptides, receptor binding, and synthetic methods (e.g., Journal of Medicinal Chemistry, 1990s publications).
- Regulatory guidance from FDA on peptide therapeutics.
More… ↓
⤷ Start Trial
|
